Aris Global's agClinical NW Becomes

Aris Global's agClinical NW Becomes

An SAP-Endorsed Business Solution

agClinical NW Integrated with SAP® Applications to Provide a Fully Functional CTMS with Finance and Real-Time Supplies Management Functionality

STAMFORD, Conn.--(BUSINESS WIRE)--Aris Global today announced that its agClinical NW, a clinical trials management system for SAP® solution-enabled environments, is now an SAP-endorsed business solution. Solutions endorsed by SAP AG are complementary to SAP software offerings, are developed in accordance with SAP development guidelines, and provide additional choices and flexibility for businesses running SAP applications.

The solution is a clinical trial management system (CTMS) integrated with SAP ERP application-based finance and supplies-management systems. Certified as "Powered by SAP NetWeaver®", agClinical NW 2.0. allows customers to leverage their investments in solutions from both SAP and Aris Global . This integration enables an organization's entire research community to utilize a secure portal to set up, plan, track and control the full range of clinical trial activities in accordance with international standards, thereby keeping trials on track, on budget, and on time.

"agClinical NW, now endorsed by SAP, delivers significant return on investment for customers," said Simon Sparkes, vice president, corporate strategy and marketing, Aris Global. "Complex global trials depend on effective coordination, collaboration and communication, and it is exactly that level of investigator relationship management that agClinical enables. The ability of agClinical NW to leverage the business potential of assets provided by solutions from SAP and other vendors will prove highly beneficial to current and future customer engagements."

agClinical's centralized platform provides end-to-end process support for clinical operations, clinical supplies, investigator budgets and payments, grant creation, and investigator self-registration. From the investigator portal, users have role-based access to exactly the data needed for daily work and decision making. The investigator portal provides key information to the study site regarding progress, document and activity tracking, notifications and alerts, and supplies accountability.

As part of the endorsed business solution agreement between Aris Global and SAP, both companies will share technology and product roadmaps, as well as market agClinical NW.

"By endorsing solutions such as agClinical NW, SAP continues to build its ecosystem, support our customers' businesses, drive new levels of collaboration, and provide additional choices and flexibility to our customers," said John Papandrea, senior vice president and head, Global Healthcare Sector, SAP. "The use of agClinical NW with SAP solutions will enable our customers to improve efficiencies with the integration of clinical supplies and financials with clinical trials management, thus facilitating the acceleration of the innovation lifecycle and faster release of life-saving products to the market."

About Aris Global

Aris Global (www.arisglobal.com) is a leading provider of integrated software solutions for pharmacovigilance and safety, regulatory affairs, clinical research and medical information. More than 300 life science companies rely on the company's advanced solutions for maintaining regulatory compliance, managing and mitigating risk, improving operational efficiency and easily sharing information on a global basis.

# # #

Aris Global and agClinical NW are trademarks or registered trademarks of Aris Global.

SAP, SAP NetWeaver and all SAP logos are trademarks or registered trademarks of SAP AG in Germany and in several other countries.

All other product and service names mentioned herein are the trademarks of their respective owners.

SAP Forward-looking Statement

Any statements contained in this document that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions as they relate to SAP are intended to identify such forward-looking statements. SAP undertakes no obligation to publicly update or revise any forward-looking statements. All forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations The factors that could affect SAP's future financial results are discussed more fully in SAP's filings with the U.S. Securities and Exchange Commission ("SEC"), including SAP's most recent Annual Report on Form 20-F filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates.

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.